Company intelligence / Profile preview

Beatrice Korea

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Viatris Korea is the South Korean subsidiary of Viatris Inc., a global healthcare company formed in 2020 through the merger of Mylan and Pfizer's Upjohn business. The company provides a broad portfolio of medicines, including iconic legacy brands such as Lipitor, Norvasc, and Lyrica, as well as generics and biosimilars. Viatris Korea focuses on addressing non-communicable diseases (NCDs) and chronic conditions, including cardiovascular health, pain management, and mental health. The company is headquartered in Seoul and operates with a mission to provide high-quality healthcare access at every stage of life.

Therapeutic areas: CardiovascularNeurologyRheumatologyMen's HealthOphthalmology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Biocon BiologicsOyster Point PharmaMeda

Beyond the preview

Go deeper on Beatrice Korea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beatrice Korea.

Explore the full profile